Let do the math... COVID-19 revenue = 10-20 b
Post# of 155000
(Total Views: 665)
Posted On: 06/24/2020 1:47:52 AM
Let do the math...
COVID-19 revenue = 10-20 billion
HIV duel revenue = 5 billion
MTNBC revenue = 60 billion
For argument sake let’s call it low at 75 billion revenue predicted in 2021
We have a total of 4 possible FDA approvals this year to make that happen.
1) COVID-19 mild to moderate
2) COVID-19 severe
3) HIV Duel therapy
4) MTNBC...
All could happen in the next couple of months. Or before the end of the year. What’s our stock worth at 75 billion projected income for 2021?
Hers and Hers2 breast cancer is worth 15 billion in current market and MTNBC Has 4 times the potential revenue and is really doing well with both Hers and Hers2 also. So might be more market share in Breast cancer than just mTNBC. What about the Basket trial for the other 21 cancers? Is that a early next year approval or late next year?
Do you think that same mechanism of action can be proved by mTNBC trials and the other Cancer indications In trial now just by mechanism of action? Do we see this as a long trial? With cancer approvals this company rockets
COVID-19 revenue = 10-20 billion
HIV duel revenue = 5 billion
MTNBC revenue = 60 billion
For argument sake let’s call it low at 75 billion revenue predicted in 2021
We have a total of 4 possible FDA approvals this year to make that happen.
1) COVID-19 mild to moderate
2) COVID-19 severe
3) HIV Duel therapy
4) MTNBC...
All could happen in the next couple of months. Or before the end of the year. What’s our stock worth at 75 billion projected income for 2021?
Hers and Hers2 breast cancer is worth 15 billion in current market and MTNBC Has 4 times the potential revenue and is really doing well with both Hers and Hers2 also. So might be more market share in Breast cancer than just mTNBC. What about the Basket trial for the other 21 cancers? Is that a early next year approval or late next year?
Do you think that same mechanism of action can be proved by mTNBC trials and the other Cancer indications In trial now just by mechanism of action? Do we see this as a long trial? With cancer approvals this company rockets
(2)
(0)